Citing high workload, the US Food and Drug Administration (USFDA) has increased the fee for processing Abbreviated New Drug Applications (ANDA) by over USD 1 lakh to USD 1.71 lakh for the fiscal year 2018.
The move will hurt the Indian pharma industry which is heavily dependent on the US market for exports, said a top official of Pharmaceuticals Export Promotion Council of India (Pharmexcil), a body under the Ministry of Commerce and Industry.
The hike was made under the Generic Drug User Fee Amendments of 2017 (GDUFA II). The fee in FY17 was USD 70,480.
According to a notification on USFDA's website, the fee for Drug Master File was reduced to USD 47,829 for 2017-18 from USD 51,140 in the last fiscal.
"The FY 2018 application fee is estimated by dividing the number of FAEs that will pay the fee in FY 2018 (948) into the fee revenue amount to be derived from ANDA application fees in FY 2018 (USD 162,888,000). The result, rounded to the nearest dollar, is a fee of USD 171,823 per ANDA," FDA said in a statement.
These fees are effective on October 1 2017, and will remain in effect through September 30, 2018.
"Though there are different categories of fee structures, definitely the hike is going to be a burden for Indian Pharma companies. However, given the potential, this would not deter us from filing ANDAs for the US market," director general of Pharmexcil, Uday Bhaskar told
(This article has not been edited by Zeebiz editorial team and is auto-generated from an agency feed.)